[go: up one dir, main page]

MX2018010559A - Procedimiento y nuevos productos intermedios para la preparacion de 11-metilen-esteroides. - Google Patents

Procedimiento y nuevos productos intermedios para la preparacion de 11-metilen-esteroides.

Info

Publication number
MX2018010559A
MX2018010559A MX2018010559A MX2018010559A MX2018010559A MX 2018010559 A MX2018010559 A MX 2018010559A MX 2018010559 A MX2018010559 A MX 2018010559A MX 2018010559 A MX2018010559 A MX 2018010559A MX 2018010559 A MX2018010559 A MX 2018010559A
Authority
MX
Mexico
Prior art keywords
preparation
steroids
methylene
procedure
intermediate products
Prior art date
Application number
MX2018010559A
Other languages
English (en)
Other versions
MX386828B (es
Inventor
Miguel Sandoval Rodríguez Celso
Herráiz Sierra Ignacio
MESSINA Ivano
Miguel Iglesias Retuerto Jesús
Original Assignee
Bionice S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionice S L U filed Critical Bionice S L U
Publication of MX2018010559A publication Critical patent/MX2018010559A/es
Publication of MX386828B publication Critical patent/MX386828B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/005—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C07J33/007—Cyclic thioketals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un procedimiento para la preparación de 11-metilenesteroides a través de la olefinación selectiva de la cetona en la posición 11. Los productos resultantes son productos intermedios útiles en la preparación de varios principios farmacéuticamente activos, tales como etonogestrel y desogestrel.
MX2018010559A 2016-03-03 2017-03-02 Procedimiento y nuevos productos intermedios para la preparación de 11-metilen-esteroides. MX386828B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382092 2016-03-03
PCT/EP2017/054952 WO2017149091A1 (en) 2016-03-03 2017-03-02 Process and new intermediates for the preparation of 11-methylene steroids

Publications (2)

Publication Number Publication Date
MX2018010559A true MX2018010559A (es) 2019-03-28
MX386828B MX386828B (es) 2025-03-19

Family

ID=55628968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010559A MX386828B (es) 2016-03-03 2017-03-02 Procedimiento y nuevos productos intermedios para la preparación de 11-metilen-esteroides.

Country Status (7)

Country Link
US (2) US11034716B2 (es)
EP (2) EP3865501B1 (es)
JP (2) JP7264569B2 (es)
ES (2) ES2881336T3 (es)
HU (2) HUE071989T2 (es)
MX (1) MX386828B (es)
WO (1) WO2017149091A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108840895B (zh) * 2018-04-24 2020-09-04 上海共拓医药化工有限公司 依托孕烯以及去氧孕烯中间体的制备方法
CN115260265A (zh) * 2022-08-19 2022-11-01 上海共拓医药化工有限公司 一种制备11-亚甲基药物中间体的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI54128C (fi) 1972-12-09 1978-10-10 Akzo Nv Foerfarande foer framstaellning av nya 11,11-alkylidensteroider ur oestran- och 19-norpregnanserien med foerbaettrad hormonell verkan
ZA94715B (en) * 1993-02-08 1994-10-24 Akzo Nv Steroids for treating menopausal complaints
JP3377856B2 (ja) * 1993-03-25 2003-02-17 イスクラ産業株式会社 骨吸収抑制・骨形成促進化合物
AU770331B2 (en) 1999-09-06 2004-02-19 N.V. Organon Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11
ITMI20021755A1 (it) 2002-08-02 2002-11-01 Poli Ind Chimica Spa Processo e nuovi intermedi per la preparazione di steroidi ad attivita' progestinica.
CN1865276A (zh) 2005-05-20 2006-11-22 上海迪赛诺化学制药有限公司 合成甾体孕激素的方法
ITMI20060474A1 (it) * 2006-03-16 2007-09-17 Ind Chimica Srl Professo ed intermedi per la preparazione di 11-metilen-18-metilestr-4-en-3,17-dione
CN101440112B (zh) * 2008-12-19 2011-04-20 北京紫竹药业有限公司 甾体化合物及其用途
CN102964418B (zh) 2010-06-25 2015-04-15 华润紫竹药业有限公司 去氧孕烯的制备工艺及其中间体化合物
US20130123523A1 (en) 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
HUE046656T2 (hu) 2012-03-15 2020-03-30 Merck Sharp & Dohme Kombinált szintézisútvonal etonogestrel és desogestrel számára
ITMI20121472A1 (it) 2012-09-04 2014-03-05 Ind Chimica Srl Processo per la preparazione di 11-metilen-18-metilestr-4-en-3,17-dione, utile come intermedio per la sintesi di molecole ad attivita' farmacologica
CN105906680A (zh) * 2016-04-27 2016-08-31 华润紫竹药业有限公司 去氧孕烯的制备方法和中间体化合物

Also Published As

Publication number Publication date
EP3865501B1 (en) 2025-04-30
JP2021183627A (ja) 2021-12-02
US11034716B2 (en) 2021-06-15
US20190092807A1 (en) 2019-03-28
EP3865501A1 (en) 2021-08-18
HUE055367T2 (hu) 2021-11-29
JP2019512481A (ja) 2019-05-16
ES2881336T3 (es) 2021-11-29
WO2017149091A1 (en) 2017-09-08
MX386828B (es) 2025-03-19
US20210269474A1 (en) 2021-09-02
ES3037073T3 (en) 2025-09-26
US12227537B2 (en) 2025-02-18
JP7264569B2 (ja) 2023-04-25
EP3423464A1 (en) 2019-01-09
EP3423464B1 (en) 2021-05-26
JP7419302B2 (ja) 2024-01-22
HUE071989T2 (hu) 2025-10-28

Similar Documents

Publication Publication Date Title
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2021014747A (es) Sistemas y metodos para sintetizar productos quimicos, incluyendo ingredientes farmaceuticos activos.
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
CL2023001293A1 (es) Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado
MX2018000064A (es) Composiciones que contienen poblaciones multiples de microcapsulas que comprenden perfume.
MX386005B (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
JOP20170100B1 (ar) توليف مركبات إندازول
CO2017002472A2 (es) Formulación de acetato de abiraterona
CL2020001073A1 (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
GT201700138A (es) Pirazolpiridinaminas
PH12017501309A1 (en) Crystalline modification of propanil
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MY183068A (en) Pharmaceutical formulation comprising antibody
ECSP17018513A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
MX2018010559A (es) Procedimiento y nuevos productos intermedios para la preparacion de 11-metilen-esteroides.
MX382220B (es) Rellenos encapsulados.
EA201890271A1 (ru) Составы для повышения эффективности гидрофобных лекарственных средств
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
MX379371B (es) Composiciones.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
GR20150100035A (el) Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου
MX2017008100A (es) Un proceso para la produccion de complejos de caseina n-acetil-aspartilada de hierro (iii) y uso de los mismos en composiciones farmaceuticas.